Heloisa Soares, MD, assistant professor, University of New Mexico Cancer Center-Albuquerque, outlines current barriers to achieving positive outcomes in neuroendocrine tumors (NETs) and what's in store for the future.
Heloisa Soares, MD, assistant professor, University of New Mexico Cancer Center-Albuquerque, outlines current barriers to achieving positive outcomes in neuroendocrine tumors (NETs) and what's in store for the future.
Transcript
What are the biggest barriers to achieving positive outcomes in neuroendocrine tumors?
I think there are a few issues that we have to think of. Number one, patients are diagnosed rather late in the game, so by the time of diagnosis, most patients are already in stage 4 metastatic disease, so the chances of actually curing the disease are much less. We also can do a much better job in terms of paraclinical science. You know, neuroendocrine tumors are very challenging for paraclinical in vitro models, mice models, and things like that. So, once we develop more of that, I think it will be easier to translate research to the bedside.
And then, finally, I think we know we certainly need more attention from funding resources to focus on giving more research money and support for neuroendocrine tumor research so more scientists and physicians can focus on that. I think if we some of this taken care of, I think the advances in neuroendocrine tumor research would be upcoming.
What’s in the future for the treatment of neuroendocrine tumors?
I think just stay tuned for the new therapies that are coming up. There is an exciting trial coming up with cabozantinib. It’s a phase 3 trial that will hopefully give us another option of therapy for patients. If this trial ends up being positive, I think we should look forward to the results of this, which might take several years to come. But, I would encourage patients, if they were given the opportunity to consider participation on this trial, to do so because I think it’s an important trial.
We are also going to be hearing about several trials talking probably about sequencing of treatment in the era of peptide receptor radionuclide therapy (PRRT), and we don’t know the right sequence of treatment right now with PRRT, and I think the trials that are being designed and will be conducted in the near future will be very important to help us guide this a little bit more.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
AUA Session Highlights the General Urologist’s Role in Gender-Affirming Care
May 7th 2024During her session, Polina Reyblat, MD, Kaiser Permanente Los Angeles Medical Center, highlighted best practices urologists should incorporate to make transgender and gender-diverse patients comfortable during physical exams and avoid retraumatization.
Read More